Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



July 2011, Volume 41 Number 7 , p 18 - 18



Linagliptin (Tradjenta), a dipeptidyl peptidase-4 inhibitor, has been approved by the FDA as an adjunct to diet and exercise to help improve glycemic control in adults with type 2 diabetes. Linagliptin was tested in eight double-blind, placebo-controlled studies involving about 3,800 patients with type 2 diabetes. The studies showed improved glycemic control when linagliptin was used as monotherapy and in combination with drugs such as metformin, glimepiride, and pioglitazone.Common adverse reactions to linagliptin include upper respiratory infection, rhinitis, nasopharyngitis, myalgia, and headache. The drug shouldn't be used in patients with type 1 diabetes or those with diabetic ketoacidosis.Source: U.S. Food and Drug Administration. FDA approves new treatment for type 2 diabetes. .The FDA released final guidance to drug companies that manufacture, market, or distribute over-the-counter (OTC) liquid medications

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: